Battle against pain prompts Johnston man to hold event 
The Des Moines Register - Aug 21 2:22 AM
Joe Kelly knows first-hand how back pain can make life difficult. He wants to help others with spinal problems by holding Super Cruise, a fundraiser…Save to My Web

Afternoon surgery may be more risky 
Detroit News - Aug 24 10:57 PM
RALEIGH, N.C. — Savvy patients know that early July, when new interns start work, is not the best time to enter a hospital. Weekends and holidays may pose problems, too.Save to My Web

‘Mint’ Pain Killer Takes Leaf Out Of Ancient Medical Texts 
Science Daily - Aug 22 9:13 AM
A new synthetic treatment inspired by ancient Greek and Chinese remedies could offer pain relief to millions of patients with arthritis and nerve damage, a new University of Edinburgh study suggests.Save to My Web

Ever-happy Mice May Hold Key To New Treatment Of Depression 
Science Daily - Aug 23 3:14 PM
A new breed of permanently “cheerful” mouse is providing hope of a new treatment for clinical depression. TREK-1 is a gene that can affect transmission of serotonin in the brain. By breeding mice with an absence of TREK-1, researchers were able create a depression-resistant strain. The details of this research, which involved an international collaboration with scientists from the University of Save to My Web

HOLLY Column 
Bridgeton News - Aug 23 7:13 AM
Good morning! The Millville High football team has a coaching staff in place. Guess who the one constant is? Bob Hogan.Save to My Web

Doctor: Lyme overdiagnosed, overtreated 
Athens Review Online - Aug 23 1:45 PM
By Patricia Cronin THE SALEM NEWS (SALEM, Mass.) DANVERS, Mass. As the four women compared notes, it seemed more like they were swapping war stories. One of them even displayed a scar on her chest, pointing to the spot where she had heart surgery.Save to My Web

Critical Therapeutics Announces Results of Phase I/II Trial of Intravenous Formulation of Zileuton 
[Press Release] Business Wire via Yahoo! Finance - Aug 23 5:00 AM
LEXINGTON, Mass.—-Aug. 23, 2006–Critical Therapeutics, Inc. today announced the results of its Phase I/II clinical trial designed to evaluate safety, tolerability and pharmacokinetics of the intravenous formulation of zileuton in patients with asthma.Save to My Web